The inclusion of anti-PD-L1 was aimed at capitalizing upon the highly expressed PD-L1 receptor on the surface of tumor cells and tumor-infiltrating lymphocytes (TIL) [18–20]. This evidence concerns the gene CD274 and neoplasm.